Denali Therapeutics (DNLI) Stifel 2026 Virtual CNS Forum summary

Key milestones and regulatory updates

• 2026 is positioned as a pivotal year with the anticipated first approval for tividenofusp alfa in Hunter syndrome, targeting both peripheral and neurological symptoms.

• The PDUFA date for tividenofusp alfa was shifted from January 5th to April 5th due to a molecular weight miscalculation, with CMC review now completed and final label discussions ongoing.

• Confidence in approval is based on robust clinical and biomarker data, with active engagement and constructive dialogue with the FDA.

• Initial launch expectations focus on patient starts rather than revenue, with minimal revenue projected for the first year.

• Teams are prepared for launch, and the company is ready to file its next molecule.

Pipeline progress and future plans

• New data on the Sanfilippo program was presented, with key efficacy cohorts fully enrolled and a data cut expected in September; BLA filing and potential approval targeted for 2027.

• Three new clinical trials are starting: two in Alzheimer's and one in Pompe, with proof-of-concept readouts expected in 2027.

• The Pompe program leverages transferrin receptor technology to enhance muscle delivery, aiming for head-to-head competition in LOPD and addressing CNS involvement in IOPD.

• The TV platform is being expanded to multiple programs, with a focus on accelerating and broadening the portfolio.

Scientific and competitive landscape

• The transferrin receptor approach is seen as a significant leap over existing therapies, enabling brain delivery and robust peripheral treatment.

• Differentiation in the Abeta brain shuttle program centers on faster plaque reduction, lower ARIA rates, and improved tolerability through engineering innovations like the cis-LALA mutation.

• The tau conjugate program is supported by convincing preclinical data for brain delivery of oligonucleotides, though muscle delivery does not directly de-risk CNS translation.

• The competitive field is rapidly expanding, but success is expected to depend on deep engineering expertise and the ability to translate that into clinical outcomes.